Navigation Links
Vermillion to Host Conference Call and Web Cast to Present Company Update and Review Financial Results for the Fourth Quarter 2010

AUSTIN, Texas, Jan. 31, 2011 /PRNewswire/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, will host a web cast and conference call to give a company update following issuance of the fourth quarter financial results on Thursday, February 10, 2011.

Conference Call Information

To access the live conference call via phone, dial (800) 920-4872 from the United States and Canada or +1 212 231-2900 internationally. The conference ID is 21509979.  Please dial-in approximately ten minutes prior to the start of the call. You may also access the live and subsequently archived web cast of the conference call from the Investor Relations section of the Company's website at Please connect to the web site at least 15 minutes prior to the call to allow for any software download that may be necessary.

A telephone replay of the call will be available beginning approximately one hour after the call through February 25, 2011, and may be accessed by dialing (800) 633-8284 from the United States and Canada or +1 402 977-9140 internationally. The replay passcode is 21509979.  An archived replay of the web cast will be available until the next quarterly call.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has diagnostic programs in oncology, hematology, cardiology and women's health.  Additional information about Vermillion can be found on the Web at

About OVA1™

OVA1™ is a qualitative serum test that combines the results of five immunoassays into a single numerical score. It is indicated for women who meet the following criteria: over age 18, ovarian adnexal mass present for which surgery is planned, and not yet referred to an oncologist. The test utilizes five well-established biomarkers - Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), beta 2-Microglobulin (beta 2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II) - and a proprietary FDA-cleared software device to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned. OVA1™ is a trademark of Vermillion, Inc.  Additional information about OVA1™ can be found on the Web at

Forward-Looking Statement

Certain matters discussed in this press release contain forward-looking statements that involve significant risks and uncertainties, including statements regarding Vermillion's plans, objectives, expectations and intentions. These forward-looking statements are based on Vermillion's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, Vermillion notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. Factors that could cause actual results to materially differ include but are not limited to: (1) uncertainty as to Vermillion's ability to protect and promote its proprietary technology; (2) Vermillion's lack of a lengthy track record successfully developing and commercializing diagnostic products; (3) uncertainty as to whether Vermillion will be able to obtain any required regulatory approval of its future diagnostic products; (4) uncertainty of the size of market for its existing diagnostic tests or future diagnostic products, including the risk that its products will not be competitive with products offered by other companies, or that users will not be entitled to receive adequate reimbursement for its products from third party payors such as private insurance companies and government insurance plans; (5) uncertainty that Vermillion will successfully license or otherwise successfully partner with third parties to commercialize its future products; (6) uncertainty whether the trading in Vermillion's stock will become significantly less liquid; and (7) other factors that might be described from time to time in Vermillion's filings with the Securities and Exchange Commission. All information in this press release is as of the date of this report, and Vermillion expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Vermillion's expectations or any change in events, conditions or circumstances on which any such statement is based, unless required by law.  

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q.  Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vermillion Announces Issuance of Patent for Peripheral Artery Disease
2. Vermillion Reappoints Three Directors, Approves a New Stock Incentive Plan, and Ratifies PricewaterhouseCoopers LLP as Its Accounting Firm
3. Vermillion Reports Financial Results for the Third Quarter 2010
4. Vermillion to Host Conference Call and Web Cast to Present Company Update and Review Financial Results for the Second Quarter 2010
5. Vermillion Announces Relocation of Corporate Offices to Austin, Texas
6. Vermillion Announces Issuance of Patent for Alzheimers Disease Diagnosis
7. Vermillion to Present at the Roth 22nd Annual OC Growth Stock Conference March 15 - 17, Laguna Niguel, CA
8. Vermillion Adds Peter S. Roddy to Board and Provides Corporate Update
9. Vermillion Announces the Reappointment of Officers and Confirmation of Director
10. Vermillion Announces $43.05 Million Private Placement of Common Stock
11. Vermillion Files Amended Plan of Reorganization and Exchanges Debt
Post Your Comments:
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: ... License Application (BLA) with the United States ... ABP 501, a biosimilar candidate to Humira ® ... biosimilar application submitted to the FDA and represents Amgen,s ... Sean E. Harper , M.D., executive vice president ...
(Date:11/25/2015)... 2015  Linden Care, LLC, a retail specialty pharmacy ... patients suffering from chronic pain, said today that it ... Order (TRO) enjoining Express Scripts from unilaterally terminating the ... --> --> The company said ... options. --> --> ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... November 29, 2015 , ... NewsWatch featured X-wing as ... available to consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted ... reality in the future. , It’s the future because flying cars are about to ...
(Date:11/29/2015)... ... , ... Effective immediately, every single IguanaMed scrub style will be available at ... offering a “Buy One Scrub Set, Get the 2nd Scrub Set 50% Off” for ... a discounted price. , IguanaMed’s mission is to outfit every healer around ...
(Date:11/28/2015)... ... ... at 6:00 a.m. EST until 11:59 p.m. EST, customers will be racing ... off orders $80 or more to free gifts with purchases, there will be a new ... e-commerce website for skin care and cosmetic needs, customers will save on already discounted prices. ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published ... that they are handling security in light of the recent terrorist attacks in Paris, ... attempt to stop an attack from reaching U.S. soil. Especially around special events that ...
(Date:11/27/2015)... ... 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion that ... of their purchase of lice treatment product. In addition, customers will receive a complimentary ... spokesperson. “Finding lice is a sure way to ruin the holidays, so we encourage ...
Breaking Medicine News(10 mins):